Table 2

Model for CD4 count (absolute and percentage)
CD4 absolute count*, ICC(%) = 0.65 CD4 Percentage*, ICC(%) = 60.5
Predictor Parameter Estimate (SE) p-value Parameter Estimate (SE) p-value
Intercept 7.9 (0.6) <0.0001 20.7 (5.1) 0.0001
Age at ART Initiation (months) -0.02 (0.003) <0.0001 -0.11 (0.01) 0.0004
Number of Available Visits Since ART Initiation -0.04 (0.04) 0.32 0.93 (0.7) 0.15
Gender
  Female -0.04 (0.2) 0.85 2.2 (2.0) 0.29
  Male (Reference)
Primary Caregiver
  Parent 0.3 (0.2) 0.07 1.4 (2.2) 0.52
  Other (Reference)
WHO HIV Clinical Stage -0.2 (0.2) 0.15 -1.5 (1.1) 0.18
ART Therapy
  3TC, ZDV, EFV 0.1 (0.3) 0.66 2.7 (3.0) 0.38
  Other -0.01 (0.4) 0.98 -4.0 (4.9) 0.41
  3TC, ZDV, NVP (Reference)
Time Post Initiation of ART Therapy (months) -0.10 (0.06) 0.09 3.6 (0.7) <0.0001
Squared Time Post Initiation of ART Therapy (months) 0.004 (0.002) 0.07 -0.12 (0.03) 0.0003
Interaction Between Time and Age at ART Initiation 0.001 (0.0004) 0.01 - -
Interaction Between Squared Time and Age at ART Initiation -0.3-4 (0.1-4) 0.03 - -
Interaction Between Time and Female Gender 0.05 (0.03) 0.11 - -
Interaction Between Squared Time and Female Gender -0.002 (0.001) 0.06 - -
Interaction Between Time and WHO HIV Clinical Stage 0.04 (0.02) 0.05 - -
Interaction Between Squared Time and WHO HIV Clinical Stage -0.001 (0.0007) 0.09 - -
Interaction between Time and Number of Visits - - -0.39 (0.11) 0.0003
Interaction Between Squared Time and Number of Visits - - 0.01 (0.005) 0.0018

Abbreviations: ART Antiretroviral Therapy, 3TC Lamivudine, ZDV Zidovudine, NVP Nevirapine, EFV Efavirenz, WHO World Health Organization.

*Log-transformed for analysis.

Barry et al.

Barry et al. BMC Infectious Diseases 2013 13:476   doi:10.1186/1471-2334-13-476

Open Data